MONTREAL, May 3, 2013 /CNW Telbec/ - John Lemieux, President of Myeloma
Canada, has announced the appointment of Francine Gendron, MBA, Adm. A,
to the position of Executive Director of Myeloma Canada. In this role,
Ms. Gendron will assume management of a dynamic patient organization
dedicated to meeting the needs of the multiple myeloma patient and
caregiver community in Canada. As well, she will be responsible for
building on the accomplishments of Myeloma Canada's first decade and
ensuring that the calls to action of local patient-support groups are
coordinated across the country.
Ms. Gendron and an expanded team of associates will be tasked with
increasing funding to meet Myeloma Canada's goals in education,
advocacy and research and with elevating public awareness of multiple
myeloma, a still-incurable disease.
"The appointment of Francine Gendron as Executive Director will help
ensure that Myeloma Canada remains at the forefront of a changing
healthcare model which recognizes the importance of patient
engagement", said John Lemieux.
"With the emergence of personalized medicine, guaranteeing the
integration of patient interests in the design and delivery of
healthcare services has become one of the most important roles Myeloma
Canada can play in improving healthcare outcomes", added Mr. Lemieux.
Prior to joining Myeloma Canada, Ms. Gendron held progressively more
responsible positions in association management. Most recently, she
led a national foundation dedicated to the development and support of
at-risk youth. Prior to that, she managed an important life sciences
organization, the Pharmaceutical Industry Sector Council in Quebec.
Mr. Lemieux also announced the appointment of Myeloma Canada fellow
Co-Founder, Aldo Del Col, to the newly created position of Chief
Science Advisor. Mr. Del Col, who leaves the position of Executive
Director, will bring his experience, expertise and concern for the
myeloma community to bear on an increased focus by Myeloma Canada on
its science and research portfolio, including the development of
Myeloma Canada's Research Network.
ABOUT MYELOMA CANADA
Myeloma Canada is the only national organization exclusively devoted to
the Canadian myeloma community. As a patient-driven, patient-focused
organization, Myeloma Canada has made myeloma matter by working with
leading myeloma researchers and clinicians, as well as other cancer
organizations and local support groups across Canada.
Myeloma Canada seeks to strengthen the voice of the Canadian myeloma
community and to improve the quality of life of myeloma patients, their
caregivers and families through education, awareness, advocacy and
Myeloma Canada is making myeloma matter for the over 7,000 Canadians
affected by this incurable, yet increasingly treatable cancer by:
Providing educational resources and support to patients, their families
Increasing awareness of the disease and its effects on the lives of
patients and families
Advancing research and promoting access to new drug trials in Canada
Facilitating access to new therapies, treatment options and health care
SOURCE: Myeloma Canada
For further information:
Francine Gendron, Executive Director
Telephone: (514) 426-5885
Cell: (514) 604-6554